Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder associated with the loss of cognitive function and the presence of characteristic neuropathological changes that include synaptic and neuronal loss, neurofibrillary tangles, and extracellular senile plaques composed of h-amyloid (Ah) protein deposits. The association of complement proteins, as well as acute phase proteins and reactive glia, with senile plaques in AD brain, suggests that inflammatory processes may play a role in this disease (Akiyama et al., 2000; Rogers et al., 1996) . Observational studies in which anti-inflammatory drug use has been associated with delay in the onset of AD are consistent with a contribution of inflammation to the neurodegeneration, although this might be in part due to the modulation of amyloid deposition by a subset of NSAIDs (Weggen et al., 2001 ).
C1q, a subcomponent of C1, the first component of the classical complement pathway, is able to directly bind h-amyloid that is in hsheet conformation and activate complement in vitro (Jiang et al., 1994; Rogers et al., 1992) . The activation of complement could cause lysis of neurons or trigger an inflammatory reaction that damages or compromises neuronal integrity (reviewed in Tenner and Webster, 2001 ). In AD, C1q has been shown to be associated with fibrillar Ah plaques, and with tangles (PHF1 positive), but not with early tangles (AT-8 positive) (Afagh et al., 1996; Shen et al., 2001) . The fibrillar Ah deposits were shown to correlate with cognitive decline (Cummings and Cotman, 1995) . The C1q-positive Ah plaques are associated with reactive astrocytes and microglia, which are often related to degenerative events (Afagh et al., 1996; Dickson, 1997; Griffin et al., 1998) . As a result, it has been hypothesized that C1q, via activation of complement, can play a detrimental role in the development of AD pathology, promoting an inflammatory state via the recruitment of activated glial cells.
C1q, however, is also known to enhance phagocytosis (Webster et al., 2000) , bind to apoptotic cells (Korb and Ahearn, 1997) , and down-regulate the induction of proinflammatory molecules (Tenner and colleagues, unpublished observations). More recently, neuronal synthesis of C1q, even in the absence of other complement proteins, has been detected in several injury models (Dietzschold et al., 1995; Goldsmith et al., 1997; Lee et al., 2000; Singhrao et al., 1999) . As a result, it can be hypothesized that C1q could play a protective role in early stages of neuronal injury by promoting the rapid clearance of apoptotic cells and/or cellular debris that result from an initial injury, thereby suppressing the progression of an inflammatory state (Tenner, 2001) .
In this work, we report the early presence of C1q in a previously described preclinical case of AD (Troncoso et al., 1998) . Immunohistochemical analysis of this case, which had a family history of AD, had demonstrated abundant amyloid and striking endosomal -lysosomal abnormalities (enlarged endosomes and increases in cathepsin D), previously suggested to be early markers of AD (Cataldo et al., 1996) . However, there was no gliosis and no neurofibrillary tangles detected. The data presented here demonstrating the near exclusive neuronal localization of C1q in this case contrasts with the lack of cortical neuronal staining and typical plaque C1q association seen in AD brain, and other preclinical and Down's syndrome cases.
